NCT05582239 (RESPIVAC) is a clinical trial in Severe Acute Respiratory Infection (SARI), sponsored by ANRS, Emerging Infectious Diseases.

Who is sponsoring NCT05582239?

NCT05582239 is sponsored by ANRS, Emerging Infectious Diseases.

What condition does NCT05582239 study?

NCT05582239 studies Severe Acute Respiratory Infection (SARI), Influenza, COVID-19.

Is NCT05582239 still recruiting?

NCT05582239 is currently status unknown. Last updated 17 May 2023.

Last reviewed 2023-05-17 · How we verify

NCT05582239: RESPIVAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Measure of Vaccine Effectiveness to Prevent Hospitalizations for Viral Respiratory Infections in Adults

Status unknown Last updated 17 May 2023

What this trial tests

trial in Severe Acute Respiratory Infection (SARI) in 2,400 participants. Status unknown.

Timeline

20 January 2023

Primary endpoint
20 January 2026

20 January 2026

Quick facts

Lead sponsor	ANRS, Emerging Infectious Diseases
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,400
Start date	20 January 2023
Primary completion	20 January 2026
Estimated completion	20 January 2026
Sites	8 locations across France

Conditions studied

Severe Acute Respiratory Infection (SARI) — all drugs for Severe Acute Respiratory Infection (SARI) →
Influenza — all drugs for Influenza →
COVID-19 — all drugs for COVID-19 →

Sponsor

ANRS, Emerging Infectious Diseases — full company profile →

Who can join

18 and older, any sex, with Severe Acute Respiratory Infection (SARI) or Influenza. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multicentric, observational test negative design study on adults hospitalized for Severe Acute Respiratory Infection (SARI), regardless of their vaccination status.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments.
Wang X, Li J, Liu H, Hu X, et al · · 2023 · cited 7× · PMID 36985154 · DOI 10.3390/microorganisms11030580

Verify or expand the search:

Other ANRS, Emerging Infectious Diseases trials

Trials by the same sponsor.

NCT07098481 — Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy · Phase 4 · not yet recruiting
NCT06913959 — HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM) · not yet recruiting
NCT07113106 — Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers · Phase 1, PHASE2 · recruiting
NCT05222945 — A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Pa · NA · not yet recruiting
NCT06522256 — Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of H · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05582239 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ANRS, Emerging Infectious Diseases
Last refreshed: 17 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05582239.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing